S100B and melanoma: These data are fully consistent with a mechanism in which high S100B levels found in malignant melanoma bind RSK and block its entry into the nucleus [8], which prevents the phosphorylation of nuclear-localized CREB and reduces expression of IL6 and IL6/STAT3 signaling (Fig 7A).